Figure 3
Association of LPC(14:0) with DILD patterns, causal drugs, symptom severities, and other DILD biomarkers. (A) Plasma LPC(14:0) concentrations for each DILD pattern in acute and recovery phase DILD patients. ***p < 0.001 vs. recovery phase. (B) Plasma LPC(14:0) concentrations in acute phase DILD patients treated with specific causal drugs and recovery phase DILD patients. L01BC: pyrimidine analogs; L01CD: taxanes; L01XC: monoclonal antibodies; L01XE: protein kinase inhibitors. ***p < 0.001 vs. recovery phase. (C) Plasma LPC(14:0) concentrations with cough and breathlessness scores, body temperatures, and SpO2 levels. (D) Plasma LPC(14:0) concentrations in acute phase DILD patients with or without oxygen administration. ***p < 0.001. (E) Plasma LPC(14:0) concentrations with other DILD biomarkers.
